National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dalbavancin (Xydalba®) is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.

NCPE Rapid Review Process Complete
Rapid review received 07/03/2017
Rapid review completed 28/04/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended at the submitted price

 

The HSE has approved reimbursement following confidential price negotiations November 2017.